Literature DB >> 3428124

Effects of doxorubicin on mouse heart catalase.

N D'Alessandro1, C Nicotra, M Crescimanno, L Rausa.   

Abstract

The behaviour of heart and liver catalase was studied 4 days after the administration of different doxorubicin doses to CD 1 mice. The antiblastic increased the specific activity of the heart enzyme with a clear dose-response relationship (+27% after 5 mg/kg i.p.; +61% after 7 mg/kg; + 108% after 10 mg/kg; + 147% after 15 mg/kg). This did not occur in the liver where, on the contrary, a significant reduction of catalase (-31%) was noticed after the highest dose. Analyses by gel filtration excluded the possibility that doxorubicin induces major changes in the molecular properties of heart catalase. In vivo experiments with aminotriazole, which blocks catalase irreversibly, indicated that doxorubicin stimulates the synthesis of cardiac catalase. These findings are discussed with reference to the possible mechanisms of anthracycline cardiotoxicity. The catalase elevation could represent a reaction by the heart to free radicals generated by doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428124

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  2 in total

1.  Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors:  T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity.

Authors:  Yunfang Zhang; Haitham El-Sikhry; Ketul R Chaudhary; Sri Nagarjun Batchu; Anooshirvan Shayeganpour; Taibeh Orujy Jukar; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Page Myers; Douglas C Rouse; Julie Foley; Abraham Nyska; Darryl C Zeldin; John M Seubert
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.